NYSE: TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K

Teva Pharmaceutical holds routine annual meeting, elects director and approves auditor

Filed May 28, 2026 · Period ending May 28, 2026 · ~1 min read

Key Changes

low

Shareholders elected Dr. Sol J. Barer to the board through 2029, with 628M votes in favor versus 246M against.

Item 5.07 verify on EDGAR →
low

Executive compensation approved on advisory basis with 796M votes in favor, indicating shareholder support for management pay practices.

Item 5.07 verify on EDGAR →
low

PwC reappointed as independent auditor through 2027 annual meeting with 881M votes in favor, representing strong shareholder backing.

Item 5.07 verify on EDGAR →

Summary

Teva Pharmaceutical held its 2026 annual shareholder meeting on May 28, reporting routine voting results across three standard proposals. Dr. Sol J. Barer was elected to serve a three-year board term, executive compensation received non-binding approval, and PwC was reappointed as the company's auditor through next year's meeting.

All three measures passed with majority support, though the board election saw relatively more opposition than the other items. For retail investors, this filing represents standard corporate housekeeping with no material business developments. The say-on-pay vote's strong approval suggests shareholders are generally satisfied with executive compensation practices.

The board election results are typical for annual meetings and don't signal governance concerns. Investors should watch for Teva's upcoming quarterly earnings reports and any updates on its generic drug pipeline or debt reduction efforts, as those will provide more meaningful insights into the company's operational performance and financial health than these procedural voting results.